The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 2nd 2025
Despite benefits for reducing drug costs, community oncology practices face the unintended consequences of the IRA.
FDA Approves Therapy for Children with Lower Limb Spasticity
October 24th 2019Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.
Read More
Opioid Litigation Settled for $260 Million in Lieu of Federal Trial
October 21st 2019Four pharmaceutical distributors have agreed to settle federal litigation related to the ongoing opioid epidemic for a collective $260 million, less than a day before a federal trial was set to begin in Ohio.
Read More
Positive Data Shown in Clinical Studies of Cantharidin for Treatment of Molluscum Contagiosum
October 20th 2019Three abstracts that evaluate the efficacy and safety of cantharidin (VP-102) were presented by Verrica Pharmaceuticals at the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada.
Read More
Interactions Between Emergency Contraception and Other Hormonal Contraceptives
October 19th 2019One highlight of the American Society for Emergency Contraception (ASEC) EC Jamboree was the key clinical discussions centered on drug interactions between emergency contraception and other hormonal contraceptives, including ulipristal acetate.
Read More
New Treatment Available for “Off” Episodes in Patients with Parkinson Disease
October 16th 2019Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.
Read More
Asenapine Approved as First Transdermal Patch for Treatment of Schizophrenia
October 15th 2019Officials from the FDA have approved Noven Pharmaceuticals, Inc.’s asenapine (Secuado) transdermal system, which is the first-and-only transdermal patch for the treatment of adults with schizophrenia, according to the company.
Read More